1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Evolution of MRI changes on follow-up imaging at specific time intervals^a
≤90 Days 91–365 Days >365 Days
No. 28 24 23
Time to follow-up MRI (day) Median, 46 (range, 12–90) Median, 159.5 (range, 92–365) Median, 1136 (range, 382-3022)
Follow-up MRI demonstrated rebleed (No.) 5 3 6
T1 hyperintensity 17/23 (73.9%) 12/21 (57.1%) 8/16 (50%)
T1 hyperintensity (moderate to significant) 9/17 (52.9%) 6/12 (50%) 1/8 (12.5%)
Enhancement with gadolinium 6/22 (27.3%) 7/20 (35%) 9/16 (56.2%)
Degree of enhancement (moderate to significant) 2/6 (33.3%) 1/7 (14.3%) 2/9 (22.2%)
Edema 2/23 (8.7%) 0 0
Degree of edema (moderate to significant) 1/2 (50%) – –
DWI low intensity 13/23 (56.5%) 12/17 (70.1%) 13/16 (81.2%)
ADC low intensity 14/19 (73.7%) 12/16 (75.0%) 8/13 (61.5%)
Change to Zabramski type II or III lesion 15/23 (65.2%) 17/21 (80.9%) 16/16 (100%)
Average size change (compared with original MRI) (mm) Median, 1.4 (range, −6.5 to +1.7) Median, 2.05 (range, −24.7 to +1.1) Median, −3.3 (range, −9.7 to +8.9)
Note:—– indicates no data.
↵a Denominators noted are based on the availability of the particular MRI sequence.